The study of oral AMXT 1501 Dicaprate in Combination With IV DFMO in patients with cancer

illustrative image

The company Aminex Therapeutics, Inc is commencing recruitment for the clinical trial of the Oral AMXT 1501 Dicaprate in Combination With IV DFMO.

The conditions are Cancer, Solid Tumor, Solid Carcinoma, Advanced Cancer, DIPG Brain Tumor, Ovary Cancer, Breast Cancer, Papillary Thyroid Cancer, Head and Neck Cancer, Gastric Cancer, Nsclc, Mesotheliomas Pleural, Mesothelioma Peritoneum, Esophageal Cancer, Diffuse Midline Glioma, H3 K27M-Mutant, Endometrial Cancer, Cervical Cancer, Melanoma, Colorectal Cancer.

A new clinical trial is recruiting patients in the following locations: United States.

The trial officially began on the August 8, 2022 and is planned to complete on December 31, 2023.

A Phase 1B/2A study will be conducted to establish safety and dose level of AMXT 1501 dicaprate in combination with IV DFMO, in cancer patients.

The link to the complete study profile: https://ichgcp.net/clinical-trials-registry/NCT05500508.

Clinical Research News

Considerations for the Use of Real-World Data and Real-World Evidence To Support Regulatory Decision-Making for Drug and Biological Products
Submission of comments on ICH E6 (R3) Guideline for Good Clinical Practice(GCP) - Step 2b 
ICH E6(R3) Good Clinical Practice guidance - Step 2 Public Consultation
The study of the new investigational drug for acute myeloid leukemia and myelodysplastic syndrome
Open Label study of entrectinib in ROS1 gene fusion-positive rare adult, paediatric and teenage/young adult cancers
Gasherbrum Bio, Inc is starting the study of GSBR-1290 drug in overweight or obese healthy adults
A new study of Dexpramipexole in adolescents and adults with severe Eosinophilic Asthma

Upcoming Clinical Trials

The study of oral AMXT 1501 Dicaprate in Combination With IV DFMO in patients with cancer

All jobs

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe